Analysis of the methylation status in most human digestive systems showed that TMEM240 was frequently hypermethylation in esophageal cancer (12/15, 80.0%), gastric cancer (2/2, 100%), colon cancer (38/38, 100%), rectal cancer (5/5, 100%), liver cancer (37/46, 80.4%), and pancreatic cancer (4/9, 44.4%), compared to paired adjacent normal tissues (Figure S1). Here, TMEM240 is linked to pancreatic neoplasm.